I. PURPOSE

It is the policy of the Metropolitan Police Department (MPD) to take steps to preserve the life of those experiencing opioid overdose. Naloxone is issued to trained members to treat opioid overdoses and reduce fatal overdoses in the District of Columbia. The purpose of this order is to establish guidelines and procedures governing the use of the naloxone nasal spray device.

II. PROCEDURES

A. General

1. Naloxone nasal spray reverses the effects of an opioid overdose within moments of being dispensed. Trained members may administer naloxone to subjects believed to be suffering from an opioid overdose, including Department members and Department canines exposed to opioids that appear to be suffering from an opioid overdose. If naloxone is administered to a subject who is not experiencing an opioid-related overdose, no adverse effects are anticipated. Naloxone has no harmful effect on the individual administering it.

2. Naloxone is issued to trained members for the treatment of opioid overdose victims. Members assigned to the units listed in Attachment A (Mandatory Carry List) shall be required to carry naloxone while on duty. Naloxone-equipped members shall provide immediate assistance to overdose victims in accordance with Department training.
3. In the event that a civil action is brought against an authorized member who administers Naloxone consistent with MPD policy and training while acting in a law enforcement capacity, the member will be afforded legal representation by the Office of the Attorney General.

B. Coordination and Distribution

1. The deployment of naloxone shall be restricted to members who have completed online training in the use of the Department-issued nasal spray device. Only Department-issued naloxone shall be used.

2. Naloxone-equipped members are responsible for the storage and maintenance of the nasal spray devices and for ensuring that the devices are readily accessible while the member is working. Members shall ensure that they are always equipped with naloxone when on duty. Uniformed members equipped with the outer vest carrier shall store the naloxone nasal spray device in the Department-issued outer vest pouch.

3. Deployment of naloxone nasal spray devices will be documented and distributed by the Metropolitan Police Academy (MPA).

C. Training

1. Authorized members shall complete mandatory online training on how to recognize an opioid overdose, how to administer the naloxone nasal spray device, and what follow up actions are required. MPA shall ensure that all authorized members receive mandatory naloxone training.

2. The commanding official of MPA shall ensure that members receive naloxone refresher training every two years.

D. Use

1. Naloxone-equipped members shall use naloxone only on affected persons or Department canines believed to be suffering from an opioid overdose.

2. Naloxone-equipped members who have reason to believe that an affected person or Department canine is suffering from an opioid overdose shall proceed as follows:

   a. Notify the Office of Unified Communications (OUC) to request Fire and Emergency Medical Services (FEMS) response to provide emergency medical treatment.

   b. Perform first responder treatment consistent with training. Remove the nasal spray device from its outer protective packaging and insert tip of the device into either of the subject’s nostrils and press the plunger firmly. Additional doses should be administered, in accordance with training, if needed before FEMS arrives.
c. When the subject begins returning to consciousness, notify the subject that naloxone was administered and that they might feel pain or withdrawal symptoms.

d. Upon arrival of FEMS, report the subject’s symptoms and all actions taken to facilitate appropriate emergency medical attention.

3. Whenever naloxone is administered by MPD, the administering member shall document the event in the records management system (RMS) by completing an RMS report and marking the “Naloxone (Narcan) deployed by MPD” check box found under “Incident Statistics”. Members shall describe the circumstances surrounding MPD’s use of the naloxone, to include who was treated and the number of doses that were administered by MPD, in the internal narrative of the report.

4. All naloxone uses shall be reported to the watch commander for inclusion in the watch commander’s report.

5. If the subject is a Department member, an official shall complete an injury report to document the exposure.

E. Maintenance and Inspection

1. Members shall not alter naloxone nasal spray devices in any way.

2. Naloxone shall not be left in Department vehicles after the end of the member’s shift. Naloxone should not be exposed to extreme heat or cold due to the temperature sensitivity of the medication. In general, members shall store their naloxone at room temperature between 59°F to 77°F (15°C to 25°C). Naloxone may be stored for short periods up to 104°F (40°C).

3. Naloxone-equipped members shall inspect naloxone nasal spray devices prior to the start of each shift to ensure that devices are intact and immediately report any loss or damage in accordance with GO-PER-110.11 (Uniform, Equipment, and Appearance Standards) according to the procedures set forth in Part II.F.1.

F. Replacement

1. Replacement naloxone devices are available at MPA. Devices are also available at the Command Information Center (CIC), but only after normal business hours when MPA is closed. Members shall provide MPA or the CIC watch commander with a copy of the approved RMS report documenting the deployment of naloxone in the narrative.

2. MPA shall monitor expiration of naloxone devices and distribute new devices to all naloxone-equipped members in possession of expired devices.
III. DEFINITIONS

When used in this directive, the following terms shall have the meanings designated.

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Naloxone</td>
<td>Opioid antagonist used to reverse the effects of opioid overdose through the use of a nasal spray device. By administering naloxone, commonly known by the brand-name Narcan, an opioid overdose is reversed as it displaces opioids from receptors in the brain.</td>
</tr>
<tr>
<td>2. Opioid</td>
<td>Class of drugs that include the illegal drug heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription, such as oxycodone, hydrocodone, codeine, morphine, and many others. These drugs are chemically related and interact with opioid receptors on nerve cells in the body and brain, and are often used in pain mitigation.</td>
</tr>
</tbody>
</table>

IV. ATTACHMENTS

Attachment A: Mandatory Carry List

Peter Newsham
Chief of Police

PN:KDO:MOCSMM
**Mandatory Carry List**

I. *Officers and sergeants* assigned to the following units *shall* carry their Department-issued naloxone while on duty.

<table>
<thead>
<tr>
<th>BUREAU</th>
<th>UNIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Executive Office of the Chief of Police</td>
<td>Special Liaison Branch</td>
</tr>
<tr>
<td>Homeland Security Bureau</td>
<td>Special Operations Division</td>
</tr>
<tr>
<td>Investigative Services Bureau</td>
<td>• Crime Scene Investigation Division</td>
</tr>
<tr>
<td></td>
<td>• Narcotics and Special Investigations Division</td>
</tr>
<tr>
<td></td>
<td>• Gun Recovery Unit</td>
</tr>
<tr>
<td></td>
<td>• Criminal Apprehension Unit</td>
</tr>
<tr>
<td></td>
<td>• Criminal Interdiction Unit</td>
</tr>
<tr>
<td></td>
<td>• Narcotics Enforcement Unit</td>
</tr>
<tr>
<td></td>
<td>• School Safety Division</td>
</tr>
<tr>
<td></td>
<td>• Youth and Family Services Division</td>
</tr>
<tr>
<td>Patrol Services North and South</td>
<td>Patrol Districts</td>
</tr>
</tbody>
</table>

II. *Plainclothes and casual clothes* personnel assigned to the Gun Recovery Unit and Narcotics Enforcement Unit *shall* carry their Departmental-issued naloxone while on duty.

III. *All members* participating in the Patrol Support Team Initiative *shall* carry their Departmental-issued naloxone while on duty.

IV. Any other member, whether in uniform or plainclothes, *may* carry Departmental-issued naloxone while on duty, but *must* comply with all procedures set forth in this order.